<table border="single" id="id_52d45e9a-fed2-4c60-a318-d31197a8f230" width="357" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 13. Established and Other Potentially Significant Drug Interactions</caption>
<col span="1" width="38.1%"></col>
<col span="1" width="26.6%"></col>
<col span="1" width="35.3%"></col>
<tbody>
<tr>
<td>Concomitant Drug</td>
<td>Effect on Concentration of Lamotrigine or Concomitant Drug</td>
<td>Clinical Comment</td>
</tr>
<tr>
<td>Estrogen-containing oral contraceptive preparations containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel</td>
<td>
<paragraph>↓ lamotrigine </paragraph>
</td>
<td>Decreased lamotrigine levels approximately 50%. </td>
</tr>
<tr>
<td>↓ levonorgestrel</td>
<td>Decrease in levonorgestrel component by 19%.</td>
</tr>
<tr>
<td>Carbamazepine (CBZ) and CBZ epoxide</td>
<td>
<paragraph>↓ lamotrigine </paragraph>
</td>
<td>Addition of carbamazepine decreases lamotrigine concentration approximately 40%. </td>
</tr>
<tr>
<td>? CBZ epoxide</td>
<td>May increase CBZ epoxide levels. </td>
</tr>
<tr>
<td>Phenobarbital/Primidone </td>
<td>↓ lamotrigine </td>
<td>Decreased lamotrigine concentration approximately 40%. </td>
</tr>
<tr>
<td>Phenytoin (PHT) </td>
<td>↓ lamotrigine </td>
<td>Decreased lamotrigine concentration approximately 40%. </td>
</tr>
<tr>
<td>Rifampin </td>
<td>↓ lamotrigine </td>
<td>Decreased lamotrigine AUC approximately 40%. </td>
</tr>
<tr>
<td>Valproate </td>
<td>
<paragraph>↑ lamotrigine </paragraph>
</td>
<td>Increased lamotrigine concentrations slightly more than 2 fold. </td>
</tr>
<tr>
<td>? valproate </td>
<td>Decreased valproate concentrations an average of 25% over a 3 week period then stabilized in healthy volunteers; no change in controlled clinical trials in epilepsy patients. </td>
</tr>
</tbody>
</table>